KUALA LUMPUR, 19 May 2026 – Pharmaniaga Berhad is entering a stronger earnings phase as higher government concession orders, a growing approved product list and the planned expansion of its human insulin business strengthen the healthcare group’s growth outlook for 2026.
The pharmaceutical and healthcare services group posted a 6.4% increase in net profit for the first quarter ended 31 March 2026, supported by stronger demand from government hospitals and improved order volumes under its concession business. The performance underlines Pharmaniaga’s continuing recovery after its regularisation journey and highlights the importance of public healthcare procurement as a stable earnings base.
Unlock the Full Article
This article is exclusive to The Ledger Asia Subsribers / PAID members.
Already have an account? Log in here
